<DOC>
	<DOCNO>NCT00585442</DOCNO>
	<brief_summary>The cardiovascular effect vitamin D therapy ( human ) document patient know vitamin D deficiency hyperparathyroidism ( surrogate marker inadequate vitamin D activity ) . It unknown whether cardiovascular benefit vitamin D therapy extend beyond patient general hypertensive population . We propose directly measure effect vitamin D therapy plasma renin activity ( PRA ) , plasma renin concentration ( PRC ) , renin transcription ( mononuclear leukocyte ) , blood pressure hypertensive ( otherwise healthy ) patient randomize , control , experimental trial . This first study ass vitamin D receptor ( VDR ) biological ( PRA , PRC , renin mRNA , polymorphism ) hypertensive activity patient without vitamin D deficiency . We hypothesize vitamin D inhibition renin transcription produce significant reduction PRA , PRC , renin transcription , inflammatory cytokine , SBP , DBP , potential variation VDR genotype . Such result may prove significant treatment hypertension , even modest blood pressure reduction ( 5 mmHg ) associate 14 % reduction mortality due stroke , 9 % reduction mortality due CHD , 7 % overall reduction all-cause mortality .</brief_summary>
	<brief_title>Effects Vitamin D Renin Expression Hypertensive Patients</brief_title>
	<detailed_description />
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>1 . Male female patient age &gt; 55 year . 2 . Female patient must postmenopausal , determined surgical hysterectomy 12 month history since last active menstruation 3 . Stage I hypertension ( JNC VII Criteria ) : mean systolic blood pressure ( mSBP ) 140159 mmHg mean diastolic blood pressure 90 99 mmHg ( mDBP ) 2 4 . Provide informed consent 1 . Serum vitamin D &lt; 55 pmol/L 2 . Serum calcium &gt; 10.5 mg/dL 3 . Serum phosphate ( inorganic ) &gt; 5.5 mg/dL 4 . Serum parathyroid hormone ( PTH ) &gt; 1.3 pmol/L 5 . Vitamin D supplement , calcium supplement , estrogen replacement therapy , corticosteroid ( inhaled/oral ) , hydroxymethyl glutarate CoA reductase inhibitor ( statin ) within 30 day prior randomization 6 . Stage II hypertension ( JNC VII criterion ) : mSSBP &gt; 160 mmHg mSDBP &gt; 100 mmHg 7 . Use alpha2agonists , betablockers , 2 antihypertensive medication screen 8 . Estimated creatinine clearance &lt; 30 mL/min CrockroftGault Formula 9 . History heart failure ( HF ) , acute myocardial infarction ( AMI ) , acute coronary syndrome ( ACS ) , transient ischemic attack ( TIA ) , cerebrovascular accident ( CVA ) , peripheral vascular disease ( PVD ) , know clot disorder 10 . Insulin dependent diabetes mellitus ( patient stabilize oral regimen may enrol ) 11 . History hypersensitivity reaction 1Î± , 25 ( OH ) 2 vitamin D3 ( calcitriol )</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>